With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta biosimilar to Accord BioPharma. About 50 employees who are associated with ...

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent litigation ...

Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim).

Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...

The products are expected to be available in June 2025. The US Food and Drug Administration (FDA) has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt ...

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

At the same time, 90% of U.S. prescriptions are either generics or biosimilars saving the U.S. healthcare system $445 billion in 2023 alone. Despite these achievements, there are important reforms ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy.

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are mixed. tt was supposed to be the start of a new era of ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference product manufacturer, Janssen Pharmaceuticals, which set timelines for ...